Neuroblastoma, the most frequent solid cancer of early childhood, requires accurate diagnosis, prognosis, and therapy selection due to its diverse clinical behavior and variable treatment response. Similarly, Diffuse Intrinsic Pontine Glioma (DIPG), the primary cause of brain tumor-related mortality among children, poses unique obstacles due to its location in the brainstem, rendering surgical intervention highly risky and impracticable. Thus, innovative approaches are imperative to address these complex clinical scenarios effectively.
The pioneering solution by Quibim emerges as a transformative breakthrough, integrating state-of-the-art AI algorithms, a customized imaging biomarker panel tailored for Neuroblastoma, and a robust storage and management platform, driving a paradigm shift in the analysis and utilization of medical imaging data for enhanced pediatric oncology diagnostics and treatment strategies.
A collaborative effort between top research and academic institutions and Quibim has yielded promising results in pediatric oncology through a European project called PRIMAGE. This project leverages Predictive In-silico Multiscale Analytics to support personalized cancer diagnosis and prognosis, empowered by imaging biomarkers. This partnership equips clinicians with advanced tools to enhance clinical decision-making, improving patient outcomes and predictive accuracy. Quibim, in turn, strengthens its position as a pioneer by offering innovative medical imaging solutions that harness clinical data through advanced artificial intelligence methodologies.